ClinicalTrials.Veeva

Menu

Blood Pressure Lowering Effects of Amosartan Regarding Proviso iN Patients With High Blood Pressure

Seoul National University logo

Seoul National University

Status

Completed

Conditions

Hypertension

Treatments

Drug: Amosartan

Study type

Observational

Funder types

Other

Identifiers

NCT03255551
LEARN BP

Details and patient eligibility

About

Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients with Hypertension

Full description

After taking Amozatan (AMS, amlodipine / rozanthin combination) in patients with essential hypertension, the percentage of patients who reached the mean systolic target blood pressure was evaluated

Enrollment

50 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with essential hypertension whose blood pressure is not adequately controlled by amlodipine or rosartan monotherapy
  • In patients with stage 2 hypertension (SBP 160-179 mmHg), patients requiring a combination therapy to reach the target blood pressure
  • Patients who were changed to amosartan while using other hypertensive agents

Exclusion criteria

  • Patients with hypersensitivity to dihydropyridine derivatives of amosartan
  • Women who are pregnant or who may be pregnant and breastfeeding
  • Patients with severe hepatic dysfunction
  • Patients with severe aortic stenosis
  • Patients at risk of shock
  • Patients participating in other clinical studies

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems